Geode Capital Management, LLC Graphite Bio, Inc. Transaction History

Geode Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.24 - $2.66 $39,338 - $46,714	17,562 Added 3.27%	555,153 $1.45 Million
Q3 2023 Nov 13, 2023	BUY	$2.18 - $2.77 $42,337 - $53,796	19,421 Added 3.75%	537,591 $1.33 Million
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $668,851 - $915,270	270,790 Added 109.46%	518,170 $1.35 Million
Q1 2023 May 15, 2023	BUY	$1.85 - $3.21 $8,961 - $15,549	4,844 Added 2.0%	247,380 $606,000
Q4 2022 Feb 13, 2023	BUY	$2.82 - $3.59 $63,918 - $81,370	22,666 Added 10.31%	242,536 $805,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $174,515 - $262,392	61,885 Added 39.17%	219,870 $696,000
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $554,330 - $1.35 Million	-259,033 Reduced 62.12%	157,985 $434,000
Q1 2022 May 13, 2022	BUY	$5.1 - $13.06 $753,989 - $1.93 Million	147,841 Added 54.92%	417,018 $2.13 Million
Q4 2021 Feb 11, 2022	BUY	$8.41 - $16.71 $99,246 - $197,194	11,801 Added 4.59%	269,177 $3.35 Million
Q3 2021 Nov 12, 2021	BUY	$15.81 - $28.39 $4.07 Million - $7.31 Million	257,376 New	257,376 $4.22 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.